{"title":"APOE4 Status and Cognitive Function in Middle-aged and Elderly People.","authors":"N A Pavel, M R Paun, P V Matei, I Dutu, C Tudose","doi":"10.2478/bjmg-2022-0012","DOIUrl":"https://doi.org/10.2478/bjmg-2022-0012","url":null,"abstract":"<p><strong>Introduction: </strong><i>APOE</i> is one of the prominent genes involved in the increased risk of developing Alzheimer's disease, but its effect on cognition in patients who are not yet diagnosed with dementia or mild cognitive impairment is relatively understudied. We aimed to examine the effect of ApoE4 on cognitive performance in unimpaired middle-aged and elderly persons.</p><p><strong>Materials and methods: </strong>Our study included 51 cognitively unimpaired participants divided into ApoE4 positive patients and controls by <i>APOE</i> genotyping. The following clinical and demographic characteristics were collected: age, gender, education, social status, BMI, history of medical or psychiatric disorders. Patients with current anxiety or depressive disorders were excluded. Cognitive function was evaluated using MMSE, Rey Auditory-Verbal Learning Test, Rey Complex Figure test, TMT A and B and verbal fluency test. The two groups were matched for age, sex, and education. Categorial data was analyzed using Chi-Square and continuous data using Student-T test (parametric variables) or Mann-Whitney test (non-parametric variables). Statistical significance was considered at p≤.05.</p><p><strong>Results: </strong>There were 11 (21.6%) ApoE4 positive patients and 40 (78.4%) controls. There were no significant differences between the groups regarding socio-demographic and clinical characteristics. The ApoE4 positive group performed slightly worse on cognitive evaluations compared to controls but only the mean scores of the Rey Complex Figure Test - Memory reached statistical significance (p=.019).</p><p><strong>Conclusion: </strong>Cognitive evaluation generally rendered lower scores in the ApoE4 group compared to the control group. However, only visual memory impairment scores were significantly lower in the ApoE4 positive individuals than in controls.</p>","PeriodicalId":55403,"journal":{"name":"Balkan Journal of Medical Genetics","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/11/ff/bjmg-25-013.PMC9985360.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9408553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"<i>MIR-147B</i> Regulated Proliferation and Apoptosis of Gastric Cancer Cells by Targeting <i>CPEB2</i> Via the PTEN Pathway.","authors":"Tao К, J-H Dong, D Wang, F Li, Z-T Zhang","doi":"10.2478/bjmg-2022-0007","DOIUrl":"https://doi.org/10.2478/bjmg-2022-0007","url":null,"abstract":"<p><p>The present study has been performed to illustrate the role and mechanism of microRNA-147b (<i>miR-147b</i>) in the cellular viability and apoptosis of gastric cancer (GC) cells. The GC tissues of 50 patients with complete data and the adjacent tissues were selected from Shanxi Cancer Hospital, and 3 pairs of tissues were randomly selected for microarray detection of high-expressing microRNAs. The expressions of <i>miR-147b</i> were quantified in numerous GC cell lines, i.e., BGC-823, SGC-7901, AGS, MGC-803 and MKN-45, normal tissue cell lines and 50 pairs of gastric cancer tissues. Moreover, two cell lines of <i>miR-147b</i> high-expressing used PCR quantitative analysis were selected for transfection experiments. The differentially expressed <i>miR-147b</i> was screened from 3 pairs of samples by miRNA chip. The expression of<i>miR-147b</i> was found highly expressed in gastric cancer tissues of 50 pairs of gastric cancer and adjacent tissues. The <i>miR-147b</i> found in diverse range in each of GC cell line. Therefore, two cell lines, BGC-823 and MGC-803, with relatively high expression levels of <i>miR-147b</i> were selected for further analysis and research. Scratch analysis results showed that compared with <i>miR-147b</i> NC, the <i>miR-147b</i> inhibitor group inhibited GC cell growth and reduced cell migration. The early apoptosis of MGC-803, and BGC-823 cells was enhanced by <i>miR-147b</i> inhibitor. <i>miR-147b</i> inhibitor significantly repressed the proliferation of BGC-823 and MGC-803 cells. Our study showed that the high expression of <i>miR-147b</i> is positively correlated with the occurrence and development of gastric cancer.</p>","PeriodicalId":55403,"journal":{"name":"Balkan Journal of Medical Genetics","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/a4/bjmg-25-061.PMC9985365.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9408556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Identification of Key Target Genes and Pathway Analysis in Nonalcoholic Fatty Liver Disease Via Integrated Bioinformatics Analysis.","authors":"X Chen, L Zhang, Y Wang, R Li, M Yang, L Gao","doi":"10.2478/bjmg-2022-0006","DOIUrl":"https://doi.org/10.2478/bjmg-2022-0006","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed at exploring the mechanisms underlying nonalcoholic fatty liver disease (NAFLD) and developing new diagnostic biomarkers for nonalcoholic steatohepatitis (NASH).</p><p><strong>Methods: </strong>The microarray dataset GES83452 was downloaded from the NCBI-GEO database, and the differentially expressed RNAs (DERs) were screened between the NAFLD and non-NAFLD samples of the baseline and 1-year follow-up time point group based on the Limma package.</p><p><strong>Results: </strong>A total of 561 DERs (268 downregulated and 293 upregulated) were screened in the baseline time point group, and 1163 DERs (522 downregulated and 641 upregulated) were screened in the 1-year follow-up time point group. A total of 74 lncRNA-miRNA pairs and 523 miRNA-mRNA pairs were obtained in order to construct a lncRNA-miRNA-mRNA regulatory network. Subsequently, functional enrichment analysis revealed 28 GO and 9 KEGG pathways in the ceRNA regulatory network. <i>LEPR</i> and <i>CXCL10</i> are involved in the Cytokine-cytokine receptor interaction (<i>P</i> = 1.86E-02), and the <i>FOXO1</i> is involved in both the insulin signaling pathway (<i>P</i> = 1.79E-02) and the pathways in cancer (<i>P</i> = 2.87E-02).</p><p><strong>Conclusion: </strong><i>LEPR</i>, <i>CXCL10</i>, and <i>FOXO1</i> were the characteristic target genes for NAFLD.</p>","PeriodicalId":55403,"journal":{"name":"Balkan Journal of Medical Genetics","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/7f/bjmg-25-025.PMC9985361.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9408560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jelic M Andjelic, D Radojkovic, A Nikolic, Lj Rakicevic, T Babic, D Jelic, N M Lalic
{"title":"Matrix Metalloproteinase-2 (<i>MMP-2</i>) and-9 (<i>MMP-9</i>) Gene Variants and Microvascular Complications in Type 2 Diabetes Patients.","authors":"Jelic M Andjelic, D Radojkovic, A Nikolic, Lj Rakicevic, T Babic, D Jelic, N M Lalic","doi":"10.2478/bjmg-2022-0001","DOIUrl":"https://doi.org/10.2478/bjmg-2022-0001","url":null,"abstract":"<p><p>Vascular complications are the leading cause of increased morbidity and mortality of diabetic patients. It has been postulated that matrix metalloproteinases <i>MMP-2</i> and <i>MMP-9</i>, zinc-dependent endopeptidases through remodeling of the extracellular matrix, can contribute to the onset and progression of diabetic vascular complications. The aim of our study was to assess whether there is a major difference in single nucleotide polymorphisms in the <i>MMP-2</i> (at position -1306C˃T) and <i>MMP-9</i> (at position -1562C˃T) gene in type 2 diabetic patients and healthy controls and to determine whether there is an association of these gene variants with the presence of microvascular complications in diabetic patients. Our study included 102 type 2 diabetes patients and a control group which was comprised of 56 healthy controls. All diabetic patients were screened for microvascular diabetes complications. Genotypes were detected by polymerase chain reactions followed by restriction analyses with specific endonucleases and their frequencies were determined. The <i>MMP-2</i> variant -1306C>T showed a negative correlation with type 2 diabetes (p=0.028). It was also shown that the presence of the -1306C allele increases the probability of developing type 2 diabetes. This was a 2.2 fold increase and that the -1306 T allele has a protective role in regards to type 2 diabetes. The <i>MMP-2</i> variant -1306T showed a negative correlation with diabetic polyneuropathy (p=0.017), meaning that allele-1306T has a protective role in regards to diabetic polyneuropathy while the presence of allele -1306C increases the probability of developing diabetic polyneuropathy by 3.4 fold. Our study showed that the <i>MMP-2</i> gene variant (-1306C) doubles the risk of developing type 2 diabetes, and for the first time an association of this gene variant and the presence of diabetic polyneuropathy was shown.</p>","PeriodicalId":55403,"journal":{"name":"Balkan Journal of Medical Genetics","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/68/f2/bjmg-25-035.PMC9985363.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9408559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A Sarajlija, L Armengol, A Maver, I Kitic, D Prokic, M Cehic, M S Djuricic, B Peterlin
{"title":"A Novel Variant in the <i>LIPA</i> Gene Associated with Distinct Phenotype.","authors":"A Sarajlija, L Armengol, A Maver, I Kitic, D Prokic, M Cehic, M S Djuricic, B Peterlin","doi":"10.2478/bjmg-2022-0010","DOIUrl":"https://doi.org/10.2478/bjmg-2022-0010","url":null,"abstract":"<p><p>Deficiency of lysosomal acid lipase (LAL-D) is caused by biallelic pathogenic variants in the <i>LIPA</i> gene. Spectrum of LAL-D ranges from early onset of hepatosplenomegaly and psychomotor regression (Wolman disease) to a more chronic course (cholesteryl ester storage disease - CESD). The diagnosis is based on lipid and biomarker profiles, specific liver histopathology, enzyme deficiency, and identification of causative genetic variants. Biomarker findings are a useful for diagnostics of LAL-D, including high plasma concentration of chitotriosidase as well as elevated oxysterols. Current treatment options include enzyme replacement therapy (sebelipase-alpha), statins, liver transplantation, and stem cell transplantation. We present two pairs of siblings from Serbia with a distinctive phenotype resembling LAL-D with a novel variant of unknown significance (VUS) detected in the <i>LIPA</i> gene and residual LAL activity. All patients presented with hepatosplenomegaly at early childhood. In siblings from family 1, compound heterozygosity for a pathogenic c.419G>A (p.Trp140Ter) variant and a novel VUS c.851C>T (p.Ser284Phe) was detected. Patients from family 2 were homozygous for c.851C>T VUS and both have typical histopathologic findings for LAL-D in the liver. Enzyme activity of LAL was tested in three patients and reported as sufficient, and therefore enzyme replacement therapy could not be approved. When confronted with a challenge of diagnosing an inherited metabolic disorder, several aspects are taken into consideration: clinical manifestations, specific biomarkers, enzyme assay results, and molecular genetic findings. This report brings cases to light which have a considerable discrepancy between those aspects, namely the preserved LAL enzyme activity in presence of clinical manifestations and rare variants in the <i>LIPA</i> gene.</p>","PeriodicalId":55403,"journal":{"name":"Balkan Journal of Medical Genetics","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0d/f0/bjmg-25-093.PMC9985358.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9408555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S Fustik, V Anastasovska, D Plaseska-Karanfilska, A Stamatova, L Spirevska, M Pesevska, M Terzikj, M Vujovic
{"title":"Two Years of Newborn Screening for Cystic Fibrosis in North Macedonia: First Experience.","authors":"S Fustik, V Anastasovska, D Plaseska-Karanfilska, A Stamatova, L Spirevska, M Pesevska, M Terzikj, M Vujovic","doi":"10.2478/bjmg-2021-0015","DOIUrl":"https://doi.org/10.2478/bjmg-2021-0015","url":null,"abstract":"<p><p>There is a widely accepted consensus on the benefits of newborn screening (NBS) for cystic fibrosis (CF) in terms of reduced disease severity, improved quality of life, lower treatment burden, and reduced costs. More and more countries in the world are introducing NBS for CF as a national preventive health program. Newborn screening for CF was introduced in the Republic of North Macedonia (RNM) in April, 2019, after a pilot study of 6 months in 2018. A two-step immunoreactive trysinogen (IRT-IRT) algorithm is performed, and then a sweat test for confirmation/exclusion of the CF diagnosis when the IRT values were both over the cutoff (70.0 and 45.0 ng/mL, respectively). In cases with confirmed diagnosis of CF (a sweat chloride concentration >60.0 mmol/L) or with intermediate sweat test results (a sweat chloride concentration of between 30.0 and 59.0 mmol/L), CF transmembrane conductance regulator (CFTR) mutation analysis is performed. By the end of 2020, over a period of 27 months, including the pilot study period, a total number of 43,139 newborns were screened for CF. Seventeen (0.039%) newborns were diagnosed with CF. In all newly discovered CF cases by screening, the diagnosis was confirmed by determination of the CFTR mutations. The most common CFTR mutation, F508del, was found with an overall incidence of 70.6%. Other more frequent mutations were G542X (11.8%) and N1303K (5.9%). Four mutations were found in one CFTR allele each: G1349D, G126D, 457TAT>G and CFTRdupexon22, with the last one being newly discovered with unknown consequences. An incredibly large difference was found in the incidence of the disease between the Macedonian and Albanian neonatal population, with almost four time higher prevalence among Albanians (1:4530 <i>vs</i>. 1:1284).</p>","PeriodicalId":55403,"journal":{"name":"Balkan Journal of Medical Genetics","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/65/02/bjmg-24-041.PMC8366466.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39356104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Z Abrahams-October, L Xhakaza, B Pearce, C Mandisa Masilela, M Benjeddou, O Vincent Adeniyi, R Johnson, J Jebio Ongole
{"title":"Genetic Association of Solute Carrier Transporter Gene Variants with Metformin Response.","authors":"Z Abrahams-October, L Xhakaza, B Pearce, C Mandisa Masilela, M Benjeddou, O Vincent Adeniyi, R Johnson, J Jebio Ongole","doi":"10.2478/bjmg-2021-0004","DOIUrl":"https://doi.org/10.2478/bjmg-2021-0004","url":null,"abstract":"<p><p>Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by elevated blood glucose levels and is influenced by both genetic and environmental factors. It is treated with various classes of oral antidiabetic drugs, however, response to treatment is highly variable with patients failing to achieve adequate glycemic control. Treatment response variability has been associated with single nucleotide polymorphisms (SNPs) which influence the pharma-cokinetics and pharmacodynamics of drug(s). The aim of this study was to evaluate the genetic association of 17 SNPs and the response to metformin therapy in patients diagnosed with diabetes from the indigenous Nguni population of South Africa. One hundred and forty indigenous African patients diagnosed with T2DM were recruited and genotyped using the MassARRAY® system. Therapeutic response of patients was ascertained by a change in Hb A<sup>1c</sup>. Two SNPs (rs1801282 and rs6265) were monomorphic. All other variants were within the Hardy-Weinberg equilibrium (HWE). The T allele of the <i>SLC</i> variant rs316009 [odds ratio (OR) = 0.25, 95% confidence interval (95% CI) = 0.01-0.09, <i>p</i> value = 0.044] and the CT genotype of the <i>PCK1</i> variant rs4810083 (OR = 2.80, 95% CI = 1.01-7.79, <i>p</i> value = 0.049) were associated with an improved response to treatment after adjustment. No association was observed with post Bonferroni correction. Moreover, this study provides important additional data regarding possible associations between genetic variants and metformin therapy outcomes. In addition, this is one of the first studies providing genetic data from the understudied indigenous sub-Saharan African populations.</p>","PeriodicalId":55403,"journal":{"name":"Balkan Journal of Medical Genetics","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/5b/bjmg-24-047.PMC8366475.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39356105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Z S Musliji, A K Pollozhani, K Lisichkov, M Deligios, Z T Popovski
{"title":"Comparative Analysis of Genes Associated with Obesity in Humans Using Bioinformatic Data and Tools.","authors":"Z S Musliji, A K Pollozhani, K Lisichkov, M Deligios, Z T Popovski","doi":"10.2478/bjmg-2021-0012","DOIUrl":"https://doi.org/10.2478/bjmg-2021-0012","url":null,"abstract":"<p><p>Obesity has become a serious global problem that still needs a solution. One of the factors that leads to obesity is genetic predisposition. The identity and characteristics of the genes involved have not yet been fully confirmed. Analyzing the genetic contribution to obesity is a major step towards the solution. In this <i>in silico</i> study, using online bioinformatics tools, we evaluate the role of four genes that are believed to contribute to obesity. Data were collected and analyzed for the sequences of four so-called obesity genes: <i>FTO</i> (fat mass and obesity-associated protein), <i>PPARG</i> (peroxisome proliferator activated receptor γ), <i>ADRB3</i> (adrenergic receptor β 3) and <i>FABP2</i> (fatty acid binding protein 2). In the first part of the research, information about the genes was collected and organized and data in FASTA, format are extracted from the National Center for Biotechnology Information (NCBI). In the second part, all genes were analyzed by comparing three species of organisms, <i>Homo sapiens</i> (human), <i>Mus musculus</i> (mouse) and <i>Gallus</i> (chicken). In the third part of this study, phylogenetic trees were constructed for each of the four genes, using blast local alignment search tool (BLAST) and molecular evolutionary genetics analysis (MEGA X) software. Our analysis reveals that the functions of all these genes are associated with overweight and obesity.</p>","PeriodicalId":55403,"journal":{"name":"Balkan Journal of Medical Genetics","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/97/88/bjmg-24-035.PMC8366471.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39356103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D Matías-Pérez, A D Pérez-Santiago, M A Sánchez Medina, J J Alpuche Osorno, I A García-Montalvo
{"title":"<i>PCSK9</i> Gene Participates in the Development of Primary Dyslipidemias.","authors":"D Matías-Pérez, A D Pérez-Santiago, M A Sánchez Medina, J J Alpuche Osorno, I A García-Montalvo","doi":"10.2478/bjmg-2021-0009","DOIUrl":"https://doi.org/10.2478/bjmg-2021-0009","url":null,"abstract":"<p><p>Dyslipidemias are a group of diseases, which are characterized by abnormal blood concentrations of cholesterol, triglycerides and/or low-density lipoprotein-cholesterol (LDL-c). Dyslipidemia is a determinant condition for the progress of an atherosclerotic plaque formation. The resulting atherogenicity is due to at least two mechanisms: first, to the accumulation in the plasma of lipid particles that have the capacity to alter the function of the endothelium and deposit at the atheromatous plaque, and second, at an insufficient concentration of multifactorial type of high density lipoprotein-cholesterol (HDL-c), whose function is to protect against the development of atherosclerosis. Its highest prevalence is encountered among individuals with diabetes, hypertension or overweight. Hyperlipidemia is one of the main predisposing factors for the development of cardiovascular disease. Hyperlipidemia can be the result of a genetic condition, the secondary expression of a primary process or the consequence of exogenous factors (food, cultural, socio-economic, <i>etc</i>.), all of which lead to the elevation of plasma lipid levels. The objective of this study was to carry out an analysis of the genes involved in the development of dyslipidemias that lead to cardiovascular disease with special emphasis on the proprotein convertase subtilin/kexin type 9 (<i>PCSK9</i>) gene. The <i>PCSK9</i> gene participates in the development of primary dyslipidemias, mainly familial hypercholesterolemia, currently the pharmacological treatment of choice to reduce LDL-c are statins, however, it has been observed that these have been insufficient to eliminate cardiovascular risk, especially in subjects with primary forms of hypercholesterolemia related to genetic mutations, or statin intolerance.</p>","PeriodicalId":55403,"journal":{"name":"Balkan Journal of Medical Genetics","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/6d/bjmg-24-005.PMC8366480.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39357170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S Sharif, A Saleem, S Naz, F Rashid, M Iqtedar, A Kaleem, A Latif
{"title":"Increased Expression of Cardiotrophin-1 in Cardiomyopathy Patients.","authors":"S Sharif, A Saleem, S Naz, F Rashid, M Iqtedar, A Kaleem, A Latif","doi":"10.2478/bjmg-2021-0008","DOIUrl":"https://doi.org/10.2478/bjmg-2021-0008","url":null,"abstract":"<p><p>Cardiomyopathy (CM) is a condition of cardiac dysfunction. It is one of the leading causes of mortality in which both genetic and environmental factors are involved. Cardiotrophin-1 (CT-1) level in plasma is associated with CM. It affects the cardiomyocyte differentiation. To evaluate the expression of CT-1 in cardiomyopathy, this study was done on CM subjects attending the Fatima Memorial Hospital, Lahore, Pakistan, between January and June, 2016. A total of 40 subjects were enrolled who were divided into two groups; CM group (<i>n</i> = 20) and a control group (<i>n</i> = 20). A self-designed questionnaire was filled in by each subject to collect data regarding age, body mass index (BMI) and CM history. RNA was isolated from blood after its quantification, cDNA was prepared and reverse-transcriptase-polymerase chain reaction (RT-PCR) was performed for expression of CT-1. The mean age in CM subjects was 40.1±6.03 years, while it was 35.0±3.7 years in the control group. The mean expression of CT-1 in the CM subjects was 5.2±0.66, while it was 1.00±0.001 in the control group. A highly significant difference was observed in CT-1 expression in the CM group, and expression was significantly correlated with age and BMI in CM subjects.</p>","PeriodicalId":55403,"journal":{"name":"Balkan Journal of Medical Genetics","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c5/ba/bjmg-24-021.PMC8366478.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39357172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}